Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
zhiqian hu
(90 results)?
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial.
JAMA Oncol. 2024 Apr 1;10(4):448-455. doi: 10.1001/jamaoncol.2023.6520.
JAMA Oncol. 2024.
PMID: 38329745
Free PMC article.
Clinical Trial.
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
Guo Y, Guo T, Di Y, Xu W, Hu Z, Xiao Y, Yu H, Hou J.
Guo Y, et al. Among authors: hu z.
Expert Opin Biol Ther. 2023 Jul-Dec;23(8):705-715. doi: 10.1080/14712598.2023.2178298. Epub 2023 Mar 9.
Expert Opin Biol Ther. 2023.
PMID: 36892190
Clinical Trial.
Item in Clipboard
Respiratory exposure to carbon black nanoparticles may induce testicular structure damage and lead to decreased sperm quality in mice.
Hu Z, Zhang Y, Zhang L, Tian Y.
Hu Z, et al.
Reprod Toxicol. 2021 Dec;106:32-41. doi: 10.1016/j.reprotox.2021.10.001. Epub 2021 Oct 6.
Reprod Toxicol. 2021.
PMID: 34624488
Item in Clipboard
The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
Hou J, Hu Z, Xu W, Di Y, Song C, Wu F, Liu J, Guo Y.
Hou J, et al. Among authors: hu z.
Int Immunopharmacol. 2022 Jun;107:108666. doi: 10.1016/j.intimp.2022.108666. Epub 2022 Mar 12.
Int Immunopharmacol. 2022.
PMID: 35286913
Clinical Trial.
Item in Clipboard
Cite
Cite